Agreement facilitates highly differentiated ADC targeting Tissue Factor
Drug Discovery World
AUGUST 21, 2024
Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.
Let's personalize your content